Current label evidence
The 13.2% trial figure is a grouped reaction rate—not a pain or bruising rate
The current Vyleesi prescribing information reports injection-site reactions in 13.2% of treated patients and 8.4% of placebo-treated patients in pooled phase 3 controlled trials. Its grouped definition includes injection-site pain, unspecified reactions, erythema, hematoma, pruritus, hemorrhage, bruising, paresthesia, and hypoesthesia. The label also reports that 1% of Vyleesi-treated patients discontinued because of injection-site reactions. These figures describe a specific FDA-approved autoinjector, trial population, and study method; they do not establish which local symptom occurred, how long it lasted, or what caused one person’s reaction.
- Do not claim that 13.2% of patients had bruising, redness, pain, or another individual symptom; the label does not separate those rates.
- The placebo rate shows that local events can reflect injection-related or other factors and should not automatically be attributed to bremelanotide itself.
- The label describes the majority of common adverse-reaction events overall as mild to moderate and transient, but it does not publish a reaction-specific size, onset, or duration cutoff.
Local symptom pattern
Describe what is happening instead of relying on “normal reaction” photos
Pain, tenderness, itching, redness, bruising, a small firm area, numbness, tingling, warmth, expanding swelling, drainage, streaking, fever, and skin-color change can have different explanations and urgency. MedlinePlus lists pain, redness, bruising, itching, numbness, or tingling where bremelanotide was injected among symptoms to report when severe or persistent. An online article or photo cannot diagnose ordinary irritation, hematoma, allergy, cellulitis, abscess, or tissue injury.
- Document when the change began, whether its border is stable or spreading, its approximate size, pain trend, warmth, firmness, drainage, fever, and symptoms elsewhere.
- Tell the clinician about easy bruising, bleeding elsewhere, anticoagulants or antiplatelet medicines, diabetes, immune suppression, circulation problems, skin disease, and adhesive or antiseptic allergy.
- A persistent, enlarging, recurrent, unusually painful, draining, or treatment-limiting reaction deserves review even if a seller calls it expected.
Product and route identity
Vyleesi evidence does not validate every product sold as PT-141
Vyleesi is an FDA-approved single-dose subcutaneous autoinjector for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Peptide12 separately lists a clinician-reviewed compounded PT-141 injection pathway. Patient-specific compounded bremelanotide is not an FDA-approved finished drug product and may differ in formulation, concentration, excipients, container, supplies, storage, and beyond-use date. Nasal products, troches, loose vials, and research-use material should not inherit Vyleesi’s reaction rate or product-quality assumptions.
- Confirm the active ingredient, route, concentration, dispensing pharmacy, prescriber, patient label, lot or prescription, storage history, and adverse-event contact.
- Report whether the reaction followed a first use, new refill, changed formulation or concentration, different device or supplies, shipment delay, temperature concern, damaged packaging, particles, cloudiness, or discoloration.
- Avoid research-use vials, no-prescription checkout, unlabeled blends, copied injection maps, reconstitution instructions, and sellers that dismiss reactions without clinician review.
What not to improvise
Do not redose, switch routes, or self-treat a concerning site from a forum protocol
The next decision depends on severity, recurrence, infection or allergy features, bleeding risk, product identity, and an examination when needed. Repeating or changing treatment, squeezing or draining a lump, vigorously rubbing the area, applying prescription creams, using leftover antibiotics, or adding an antihistamine or pain medicine can delay diagnosis or introduce interaction, allergy, sedation, bleeding, kidney, liver, or masking risks. The prescriber should decide whether treatment is held and whether the site, product, pharmacy, or adverse event needs further assessment.
- Do not use another device or supply to “test” the reaction and do not inject into irritated, sore, bruised, red, hard, scarred, or otherwise damaged skin.
- Do not stop a prescribed anticoagulant, antiplatelet medicine, or cardiovascular treatment on your own because of a local bruise or bleeding concern.
- Preserve photos and product details, but do not let portal messaging delay in-person care when symptoms are rapidly worsening or severe.
Escalation
Separate prescriber follow-up from infection and serious-allergy emergencies
A mild stable local symptom may be appropriate for prescriber follow-up, but rapidly spreading redness or swelling, severe or escalating pain, pus, red streaks, fever, skin breakdown, or feeling acutely unwell can require prompt local assessment. Widespread hives, wheezing, trouble breathing, throat tightness, facial or tongue swelling, fainting, confusion, or rapidly developing whole-body symptoms are not routine injection-site reactions and can require emergency care.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or rapidly developing widespread hives or swelling.
- Seek prompt local assessment for rapid spread, severe or disproportionate pain, pus or drainage, red streaks, fever or chills, blistering, darkening, or skin breakdown.
- Contact the prescriber for persistent, recurrent, enlarging, unusually painful, or treatment-limiting local symptoms and before another product or route decision.